Oh! Perhaps they are just starting;-) |
But they haven't started yet (my informant in JPMC), HSBC are speculating or just hoping. The investment industry seems to have been hollowed out by poor performance leading to a move to 'tracker' funds. |
British stocks represent a golden buying opportunity, HSBC has said.
The investment bank has told clients to buy UK-listed stocks, arguing that downward pressure on share prices from pension funds selling almost £2 trillion of assets has ended.
“The long-term structural overhang of UK pension fund selling is at an end; they simply have no more UK equities left to sell,” the bank’s research team said.
HSBC in fact expects retirement funds to start buying British stocks, amid political pressure to support the UK economy. |
Professor Adrian Hill, Director of the Jenner Institute at Oxford University, said, “The start of the distribution at large scale of this high efficacy, very cost-effective vaccine should mark a turning point in the battle against malaria.”
From
Hopefully a turning point for OXB too. |
Regarding the relevance of the last post there, then if Serum have started to ship the vaccines which have been manufactured in advance and kept in cold store, then they must finally have the deal from the chain of international organisations which Prof Hill was recently saying was taking far too long to get done.
Are we dusting off one of our 1,000 litre covid bioreactors as I type? |
 So, it has finally started...
Serum Institute Begins Shipments Of Malaria Vaccine 'R21/Matrix-M' To Africa
The initial shipment is being sent to the Central African Republic (CAR), followed by other African countries such as South Sudan and Democratic Republic of Congo in the coming days, it added.
New Delhi: Vaccines manufacturer Serum Institute of India (SII) on Monday said it has started exports of 'R21/Matrix-M' malaria vaccine to Africa as part of the global fight against the disease.
Developed in collaboration with the University of Oxford and Novavax's Matrix-M adjuvant, the R21/Matrix-M vaccine is the second malaria vaccine to be authorised for use in children in malaria-endemic regions, SII said in a statement.
The initial shipment is being sent to the Central African Republic (CAR), followed by other African countries such as South Sudan and Democratic Republic of Congo in the coming days, it added.
In total, 1,63,800 doses of the 'R21/Matrix-M' malaria vaccine have been specifically allocated for the CAR region, of which only 43,200 doses have been dispatched on Monday from SII's facility in Pune.
"The shipment of the 'R21/Matrix-M' malaria vaccine to Africa marks a momentous milestone in our collective fight against this life-threatening disease. This achievement is a testament to the power of collaboration and the efforts of our dedicated workforce at the Serum Institute of India, working in partnership with Novavax and the University of Oxford," SII Executive Director, R&D, Umesh Shaligram, said.
Novavax President and CEO John C Jacobs said, "The R21/Matrix-M vaccine is a vital new tool to help stop the devastating health and economic impact of malaria on nearly half of the world's population, including the tragic loss of 1,300 children every single day.". |
Mentioned many times here in the past Dom, but whilst I'm not going to put up the buntings for getting back into the £3 range when a smaller, lossmaking company was in the £5 range last year, it's still up 30%+ in a relatively short time and holding that level.
Things are not helped at present by OXB seemingly stymied by something which they can't talk about and which prevents / prevented the senior staff from buying.
We know there is this second commercial contract, which may or may not be with one of our vectors - and that's great news - but it's very unlikely to be the big secret.
We're only months away from IM giving OXB another 20m Euros for new shares. We've seen stories that Novo are looking specifically for bio services companies to place their weight loss profits into. We've talked about malaria for years now (since the Serum boss first mentioned it). Our huge pipeline (well, the fraction which isn't secret) moves ever forward each day.
I would expect something significant from OXB (on top of the good news story we know about). The timescale is the real unknown and that is likely out of their hands. Might be tomorrow / might be H2. |
The message doesn't seem to be getting through... to analysts (in particular), and investors. |
or
More process improvement. |
In the 'good old days' Friday was always an 'up' day. |
not sure about a Loch Ness Monster pattern, but it could very well be a Cup & Handle 🥳 |
I agree with all of that, but the other possibility of course is that they are simply going to manufacture someone else's vector to help with demand - so not our vector / tech improvements and therefore a straight manufacturing CMO deal rather than CDMO.
Usually the vector process is tied to the drug approval, so the vector would need to be made exactly the same way as by whoever supplied it for the trials, but that's a possibility too.
Just straight CMO style manufacturing would be less lucrative than making our own vector, but still good money for a long time. |
Thanks and as you say it doesn’t really matter who it is if one can overcome one’s impatient curiosity. The deal is done and it will be revenue accretive and it they have judged it passes the materiality threshold of being price sensitive and hence needing an RNS then whenever it comes it will be very pleasant |
Xoptimist,
It has never been clearly stated and I don't know this for certain, but my understanding is something like this:-
Juno developed the drug and target. Celgene bought Juno. BMS bought Celgene.
I'm sure you know this part but a vector is needed to turn the T-Cells into CAR-T cells with that target and Bluebird (at that time) both developed their own drugs and provided vectors for others. 270 was spun out of Bluebird.
We had a deal with Juno for some of their CAR-T and TCR-T targets but OXB have never told us which ones.
We know BMS have had supply issues (via press reports) and that they were trying all routes to get around that. We don't know what their solution was.
I think we were probably correct with discounting BMS as not a new company to us. We have existing deals with both Juno and BMS, so there's no way to spin that as new.
Similarly our deal with Arcellx (in a pivotal trial for the same disease) wouldn't make them new either.
It only really leaves J&J and as you say, to us they are a large pharmaceutical company, but, the line between a pharmaceutical company and a biotechnology company is pretty blurry and / or if OXB have done the deal with the biotechnology division of Johnson & Johnson (which actually says Jansen as the company on the approval)?
Plutonian when the RNS came out thought the best fit was Carvykti (J&J) and I can't come up with anything better.
They say the manufacturing is going to be OxBox and we know (press reports again) that the EMA has looked favourably upon Carvykti, so if you wanted my guess for tonight then I would say that a possibility here is J&J using a local Lentivector for the EMA market (i.e. OXB).
But it doesn't really matter who it is. The important thing is that the deal is already done and that we will soon have a second long term commercial supply line. The detail when it comes (hopefully soon) should clear it all up. |
I thought the discussion you guys have had about who this could be has been very smart and it’s most likely BMS or JNJ both of whom
Had FDA approvals for expanded use of their multiple myeloma therapies just 14 days after the March 20th RNS. What threw me was the wording “US biotechnology company” as neither BMS nor JNJ fit. So a question could the deal with with the junior biotech company which in the case of BMS is 2seventy bio. Is there any precedent where oxb signs a deal with the smaller biotech partner? In their recent results presentation 2seventybio also says that part of the FDA approval was for use of suspension lentiviral vector in the manufacturing of abecma. Surely this is the second commercial deal in the oxb slides which they took great pains on three occasions to say was excluded from the 104m backlog? |
I think we all know what this is likely about today.
Frank talking about finances in his piece at the results said:-
"I would like to note that this figure excludes a new order with a US client preparing for commercial launch, which we announced in March recently.".
That RNS was this one which said:-
"Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based manufacturing facility.".
So that's a signed deal where many of us have tried to guess the likely partner, but whoever it is doesn't really matter that much. What does matter is when OXB tells us the detail - and - how much it is worth to the company for how long.
For anyone looking for a very short term punt, then it seems pretty risk free doesn't it? (The deal being signed). |
Loch Ness Monster? No. Pennant. Likely |
Tomorrow may be interesting to watch if we get back above 3.40 and the momentum chaps decide to rejoin the fray on a new breakout :)
dyor/nai etc |
Hopefully Nessie is wearing a large dunce's cap... |
I need Brucie for this one really, but if you look at the 6 month chart in the thread header, isn't that the Loch Ness monster pattern forming? |
A little bit more on the Cabaletta trials reporting early data soon - it will be the 14th of June.
Quote from their boss here “With no CRS or ICANS of any grade observed in either of the first patients from the RESET-Myositis and RESET-SLE trials, we look forward to presenting initial translational and clinical data from both patients during a satellite symposium at the EULAR 2024 Congress on June 14th"
Top 2 trials on this list
Relevant OXB link for us
"Oxford Biomedica initially licensed its LentiVector® platform to Cabaletta Bio for their lead product candidate, DSG3-CAART. The agreement has now been extended to grant a non-exclusive license to Cabaletta under Oxford Biomedica’s LentiVector® platform IP for their CAR-T programme, CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Cabaletta Bio has received two IND clearances to date for CABA-201 and plans to initiate a Phase 1/2 clinical trial for patients with systemic lupus erythematosus and lupus nephritis and a separate Phase 1/2 clinical trial for patients with myositis.".
I'm not a doctor / scientist, but no unwanted / unintended effects in the first patients sounds a big deal to me - assuming that the actual disease response is good (and why would they try to showcase it at big conference if it wasn't?). |
So, back to a real meeting at the company offices then.
If you wish to attend the meeting in person, please register your intention to do so as soon as practicable by email to ir@oxb.com, but in any event no later than 3 p.m. BST on 20 June 2024.
The Company understands that the AGM also serves as a forum to engage with shareholders and shareholders’ views are always very important to us. Therefore, to support engagement, following the conclusion of the 2024 AGM, Dr. Frank Mathias, Chief Executive Officer and Stuart Paynter, Chief Financial Officer will present on the Company’s progress in 2023.Afterthe presentation, Dr. Mathias, Mr. Paynter, the other Directors and I will answer questions from shareholders. After responding to the pre-submitted questions, shareholders will be able to ask further questions in person. Shareholders are encouraged to submit questions in advance by emailing ir@oxb.com before 2.30 p.m. BST on 24 June 2024. We may choose to summarise and bundle questions thematically.
From |
Plain language PDF of the J&J Study |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
